Track the RNA clinical trial and drug landscape with Beacon RNA
What we cover
Beacon RNA is a manually curated database solution that includes clinical trial and drug data for preclinical, active, approved, and discontinued:
- Oligonucleotide-based therapies
- mRNA-Based Therapies
- Ribozyme Therapies
- gRNA-Mediated Gene Editing Therapies
- RNA-Targeted Small Molecules
Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
How Beacon helps
Here are some examples of how Beacon RNA can accelerate your research programs:
- Search for RNA drugs across all stages of development so you can accurately benchmark your strategies against other preclinical and clinical drugs, and investigate the novel approaches used by competitors.
- Drastically reduce time spent looking through publications and conference abstracts for clinical trial results by relying on our comprehensive collection of data which can be searched by route of administration, delivery system, nucleic acid modifications and much more.
- Stay on top of emerging trends and new players in the field with real-time updates and alerts, as well as in-depth monthly reports curated by our expert analyst team.
How Beacon RNA works
Search the trial and drug landscape by target organ, formulation, nucleic acid modification, editing technology, plus more, alongside many other search criteria to instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the RNA space.
How we target the data
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
Our RNA Expert
Ioana Panait, MSci, the lead research analyst for Beacon RNA.
Sign up for our weekly newsletter to uncover the latest insights into the RNA landscape using data from Beacon.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon RNA to help you, get in touch with our sales team
Will Savill & Matty Slingsby
RNA Account Managers
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.